We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current CDTX market cap is 261.88M. The company's latest EPS is USD -2.0963 and P/E is -11.37.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 12.72M | 17.58M | 8.46M | -7.19M | 0 |
| Operating Income | -8.56M | -6.07M | -10.69M | -95.36M | -17.39M |
| Net Income | -8.17M | -5.61M | -10.33M | -91.21M | -15.99M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 20.92M | 12.07M | 49.57M | 64.29M | 63.91M |
| Operating Income | -41.72M | -71.85M | -42.26M | -29.72M | -24.48M |
| Net Income | -41.09M | -74.87M | -42.47M | -29.8M | -22.93M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 63.47M | 67.03M | 52.72M | 173.36M | 162.33M |
| Total Liabilities | 55.43M | 75.24M | 70.5M | 42.42M | 46.7M |
| Total Equity | 8.04M | -8.21M | -17.78M | 130.94M | 115.63M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 68.98M | 60.42M | 75.33M | 47.59M | 67.03M |
| Total Liabilities | 31.14M | 49.71M | 53.75M | 50.5M | 75.24M |
| Total Equity | 37.84M | 10.72M | 21.57M | -2.9M | -8.21M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -9.71M | -22.43M | -6.64M | -110.42M | -147.12M |
| Investing | -327k | -505k | -23k | -23k | -129k |
| Financing | 25.98M | 25.98M | -93k | 239.04M | 238.86M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -28.53M | -54.41M | -25.23M | -28.47M | -22.43M |
| Investing | -35k | -186k | -41k | -118k | -505k |
| Financing | 14.27M | 37.28M | 44.6M | -951k | 25.98M |
| Market Cap | 261.88M |
| Price to Earnings Ratio | -11.37 |
| Price to Sales Ratio | 4.08 |
| Price to Cash Ratio | 7.29 |
| Price to Book Ratio | -31.76 |
| Dividend Yield | - |
| Shares Outstanding | 10.94M |
| Average Volume (1 week) | 105.86k |
| Average Volume (1 Month) | 96.34k |
| 52 Week Change | 76.65% |
| 52 Week High | 28.42 |
| 52 Week Low | 10.004 |
| Spread (Intraday) | 6.68 (25.21%) |
| Company Name | Cidara Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.cidara.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
